Literature DB >> 30953614

Development and Validation of a Simplified Magnetic Resonance Index of Activity for Crohn's Disease.

Ingrid Ordás1, Jordi Rimola2, Ignacio Alfaro3, Sonia Rodríguez4, Jesús Castro-Poceiro3, Anna Ramírez-Morros3, Marta Gallego3, Àngel Giner5, Rebeca Barastegui3, Agnès Fernández-Clotet3, Maica Masamunt3, Elena Ricart6, Julián Panés6.   

Abstract

BACKGROUND & AIMS: The magnetic resonance index of activity (MARIA) for Crohn's disease (CD) is used to assess the activity of luminal CD. However, it has a number of practical limitations. We aimed to develop and validate a simplified MARIA to more easily and quickly assess CD activity and response to therapy. PATIENTS AND METHODS: We performed a retrospective analysis of magnetic resonance imaging data from 98 participants in 2 studies. We used logistic regression analysis to identify magnetic resonance imaging parameters independently associated with CD endoscopic index of severity (CDEIS) scores (the reference standard). We validated the responsiveness and reliability of the simplified MARIA in an independent cohort of 37 patients who underwent magnetic resonance imaging and endoscopy before and after a therapeutic intervention.
RESULTS: Logistic regression analysis showed that dichotomous qualitative assessment of wall thickening (>3 mm), presence of mural edema, perienteric fat stranding, and ulcers were independently associated with CDEIS scores; we used these factors to create a simplified MARIA. Simplified MARIA scores greater than 1 identified segments with active CD with 90% sensitivity and 81% specificity (area under the curve 0.91; 95% confidence interval 0.88-0.94). Simplified MARIA scores of 2 or more detected severe lesions (ulcers) with 85% sensitivity and 92% specificity (area under the curve 0.94; 95% confidence interval 0.91-0.96). For each patient, there was a high level of correlation between simplified MARIA scores and CDEIS scores (r = 0.83) and simplified MARIA scores and original MARIA scores (and r = 0.93) (P < .001). The simplified MARIA score accurately detected changes in lesion severity in response to therapy and was as reliable as endoscopy for the assessment of mucosal healing.
CONCLUSION: We developed and validated a simplified MARIA for easier and faster assessment of CD activity and severity. This index identifies patients with a response to therapy with a high level of accuracy. These findings require confirmation in independent, multireader studies.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnostic; IBD; Inflammatory Bowel Disease; Prognostic

Mesh:

Year:  2019        PMID: 30953614     DOI: 10.1053/j.gastro.2019.03.051

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  17 in total

1.  The new simplified MARIA score applies beyond clinical trials: A suitable clinical practice tool for Crohn's disease that parallels a simple endoscopic index and fecal calprotectin.

Authors:  Joana Roseira; Ana Rita Ventosa; Helena Tavares de Sousa; Jorge Brito
Journal:  United European Gastroenterol J       Date:  2020-07-14       Impact factor: 4.623

Review 2.  Evolving therapeutic goals in Crohn's disease management.

Authors:  Thomas Chateau; Laurent Peyrin-Biroulet
Journal:  United European Gastroenterol J       Date:  2019-11-04       Impact factor: 4.623

Review 3.  Artificial Intelligence for Disease Assessment in Inflammatory Bowel Disease: How Will it Change Our Practice?

Authors:  Ryan W Stidham; Kento Takenaka
Journal:  Gastroenterology       Date:  2022-01-04       Impact factor: 22.682

4.  Avoiding contrast-enhanced sequences does not compromise the precision of the simplified MaRIA for the assessment of non-penetrating Crohn's disease activity.

Authors:  Agnès Fernàndez-Clotet; Víctor Sapena; Nunzia Capozzi; Sonia Rodríguez; Maria-Carme Masamunt; Elena Ricart; Ingrid Ordás; Julian Panés; Jordi Rimola
Journal:  Eur Radiol       Date:  2022-01-15       Impact factor: 5.315

5.  Crohn's disease active inflammation assessment with iodine density from dual-energy CT enterography: comparison with endoscopy and conventional interpretation.

Authors:  Bari Dane; Amelia Kernizan; Thomas O'Donnell; Robert Petrocelli; Wendy Rabbenou; Sumona Bhattacharya; Shannon Chang; Alec Megibow
Journal:  Abdom Radiol (NY)       Date:  2022-07-14

6.  Assessing the inflammatory severity of the terminal ileum in Crohn disease using radiomics based on MRI.

Authors:  Honglei Ding; Jiaying Li; Kefeng Zhou; Zhichao Sun; Kefang Jiang; Chen Gao; Liangji Lu; Huani Zhang; Haibo Chen; Xuning Gao
Journal:  BMC Med Imaging       Date:  2022-07-04       Impact factor: 2.795

7.  Defining the Path Forward for Biomarkers to Address Unmet Needs in Inflammatory Bowel Diseases.

Authors:  Gerard Honig; Caren Heller; Andrés Hurtado-Lorenzo
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325

Review 8.  Evidence-based clinical practice guidelines for inflammatory bowel disease 2020.

Authors:  Hiroshi Nakase; Motoi Uchino; Shinichiro Shinzaki; Minoru Matsuura; Katsuyoshi Matsuoka; Taku Kobayashi; Masayuki Saruta; Fumihito Hirai; Keisuke Hata; Sakiko Hiraoka; Motohiro Esaki; Ken Sugimoto; Toshimitsu Fuji; Kenji Watanabe; Shiro Nakamura; Nagamu Inoue; Toshiyuki Itoh; Makoto Naganuma; Tadakazu Hisamatsu; Mamoru Watanabe; Hiroto Miwa; Nobuyuki Enomoto; Tooru Shimosegawa; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-04-22       Impact factor: 7.527

9.  Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases.

Authors:  Quazim A Alayo; Aava Khatiwada; Anish Patel; Maria Zulfiqar; Anas Gremida; Alexandra Gutierrez; Richard P Rood; Matthew A Ciorba; George Christophi; Parakkal Deepak
Journal:  Inflamm Bowel Dis       Date:  2021-10-18       Impact factor: 7.290

Review 10.  Objective evaluation for treat to target in Crohn's disease.

Authors:  Kento Takenaka; Yoshio Kitazume; Toshimitsu Fujii; Kiichiro Tsuchiya; Mamoru Watanabe; Kazuo Ohtsuka
Journal:  J Gastroenterol       Date:  2020-03-04       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.